Inventor · disambiguated record
Rima Kaddurah-Daouk
Also filed as: KADDURAH-DAOUK RIMA · KADDURAH-DAOUK RIMA F
29 granted patents·45 pending applications·895 citations·filing 1990–2023
98Inventor score
Files withAVICENA GROUP INC17KADDURAH DAOUK RIMA F7CORNELL RES FOUNDATION INC6METABOLON INC6UNIV DUKE4
Top patents by PatentIndex Score
74 records- 0197US7550258B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsMETABOLON INC·Filed 2006·Granted Jun 23, 2009·30 cites·8 claims
- 0297US7329489B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsMETABOLON INC·Filed 2003·Granted Feb 12, 2008·86 cites·78 claims
- 0397US7005255B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsCORNELL RES FOUNDATION INC·Filed 2004·Granted Feb 28, 2006·118 cites·5 claims
- 0496US7553616B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsMETABOLON INC·Filed 2007·Granted Jun 30, 2009·23 cites·10 claims
- 0596US7550260B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsMETABOLON INC·Filed 2007·Granted Jun 23, 2009·27 cites·9 claims
- 0695US6242491B1Use of creatine or creatine compounds for skin preservationFiled 1999·Granted Jun 5, 2001·87 cites·32 claims
- 0794US7682783B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsCORNELL RES FOUNDATION INC·Filed 2005·Granted Mar 23, 2010·15 cites·6 claims
- 0894US7635556B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsCORNELL RES FOUNDATION INC·Filed 2006·Granted Dec 22, 2009·26 cites·14 claims
- 0994US7186754B2Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2005·Granted Mar 6, 2007·19 cites·11 claims
- 1093US7682784B2Methods for drug discovery disease treatment, and diagnosis using metabolomicsCORNELL RES FOUNDATION INC·Filed 2005·Granted Mar 23, 2010·13 cites·7 claims
- 1188US7947453B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsMETABOLON INC·Filed 2009·Granted May 24, 2011·6 cites·11 claims
- 1287US7910301B2Methods for drug discovery, disease treatment, and diagnosis using metabolomicsMETABOLON INC·Filed 2007·Granted Mar 22, 2011·6 cites·30 claims
- 1386US7556935B2Induction of apoptosis by cellular stressDANA FARBER CANCER INST INC·Filed 2006·Granted Jul 7, 2009·9 cites·17 claims
- 1484US5998457ACreatine analogues for treatment of obesityAVICENA GROUP INC·Filed 1996·Granted Dec 7, 1999·47 cites·20 claims
- 1584US5324731AMethod of inhibiting transformation of cells in which purine metabolic enzyme activity is elevatedAMIRA INC·Filed 1990·Granted Jun 28, 1994·77 cites·17 claims
- 1682US6075031AUse of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disordersDANA FARBER CANCER INST INC·Filed 1997·Granted Jun 13, 2000·41 cites·15 claims
- 1780US7285573B2Use of creatine or creatine analogs for the treatment of diseases of the nervous systemGEN HOSPITAL CORP·Filed 2003·Granted Oct 23, 2007·9 cites·8 claims
- 1880US6566086B1Diagnostic kit for detecting creatine levelsFAL DIAGNOSTICS·Filed 2000·Granted May 20, 2003·25 cites·33 claims
- 1979US6706764B2Use of creatine or creatine analogs for the treatment of diseases of the nervous systemAVICENA GROUP INC·Filed 1997·Granted Mar 16, 2004·45 cites·16 claims
- 2079US5676978AMethods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agentAMIRA INC·Filed 1994·Granted Oct 14, 1997·48 cites·65 claims
- 2178US6720188B2Methods and kits for the detection of arginine compoundsFAL DIAGNOSTICS·Filed 2001·Granted Apr 13, 2004·23 cites·35 claims
- 2277US5321030ACreatine analogs having antiviral activityAMIRA INC·Filed 1991·Granted Jun 14, 1994·64 cites·83 claims
- 2376US7118862B2Induction of apoptosis by cellular stressUNIV CHICAGO·Filed 2002·Granted Oct 10, 2006·11 cites·19 claims
- 2475US2010303840A1Use of creatine or creatine analogs for the treatment of diseases of the nervous systemAVICENA GROUP INC·Filed 2009·Application pending·0 cites
- 2573US2009221706A1Methods of treating cognitive dysfunction by modulating brain energy metabolismUNIV CINCINNATI·Filed 2008·Application pending·0 cites
- 2672US2010226870A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2009·Application pending·0 cites
- 2767US2007027090A1Methods of treating cognitive dysfunction by modulating brain energy metabolismCHILDRENS HOSP MEDICAL CENTER·Filed 2006·Application pending·0 cites
- 2866US2007123496A1Use of aminoguanidine or aminoguanidine analogs for the treatment of diseases of the nervous systemKADDURAH-DAOUK RIMA·Filed 2006·Application pending·0 cites
- 2966US2006241021A1Methods of treating cognitive dysfunction by modulating brain energy metabolismUNIV CINCINNATI CHILDREN S HOS·Filed 2006·Application pending·0 cites
- 3066US2014287936A1Methods for drug discovery, disease treatment, and diagnosis using metabolomicsCORNELL RES FOUNDATION INC·Filed 2013·Application pending·0 cites
- 3165US2009298943A1Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disordersAVICENA GROUP INC·Filed 2008·Application pending·0 cites
- 3265US2007253944A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2007·Application pending·0 cites
- 3362US8137977B2Lipidomic approaches to determining drug response phenotypes in cardiovascular diseaseKADDURAH-DAOUK RIMA F·Filed 2008·Granted Mar 20, 2012·3 cites·59 claims
- 3462US6169115B1Use of aminoguanidine analogs for the treatment of diseases of the nervous systemFiled 1999·Granted Jan 2, 2001·17 cites·13 claims
- 3562US2009017464A1Methods for drug discovery, disease treatment, and diagnosis using metabolomicsCORNELL RES FOUNDATION INC·Filed 2008·Application pending·0 cites
- 3662US2004116390A1Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disordersAVICENA GROUP INC·Filed 2003·Application pending·0 cites
- 3762US2012141391A1Use of creatine or creatine compounds for skin preservationKADDURAH-DAOUK RIMA·Filed 2011·Application pending·0 cites
- 3861US2005186194A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2005·Application pending·0 cites
- 3961US2004126366A1Methods of treating cognitive dysfunction by modulating brain energy metabolismFiled 2003·Application pending·0 cites
- 4061US2005226840A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2005·Application pending·0 cites
- 4161US2005186195A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2005·Application pending·0 cites
- 4260US6288124B1Methods of inhibiting undesirable cell growth using an aminoguanidine compoundFiled 1999·Granted Sep 11, 2001·19 cites·20 claims
- 4359US8394354B2Biomarkers for depression and methods using the samePAIGE LISA A·Filed 2007·Granted Mar 12, 2013·1 cites·18 claims
- 4459US2011085993A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2010·Application pending·0 cites
- 4559US2003018082A1Use of aminoguanidine or aminoguanidine analogs for the treatment of diseases of the nervous systemFiled 2002·Application pending·0 cites
- 4658US2008119450A1Use of creatine or creatine analogs for the treatment of diseases of the nervous systemAVICENA GROUP INC·Filed 2007·Application pending·0 cites
- 4758US2010329997A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2010·Application pending·0 cites
- 4858US2011008272A1Use of Creatine or Creatine Compounds for Skin PreservationAVICENA GROUP INC·Filed 2010·Application pending·0 cites
- 4958US2011021632A1Use of creatine or creatine compounds for skin preservationAVICENA GROUP INC·Filed 2010·Application pending·0 cites
- 5057US2024183845A1Bile acid metabolites for diagnosing and treating depressive disordersKADDURAH DAOUK RIMA F·Filed 2022·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →